Компания Oliva Therapeutics запустила новую гормональную терапию Amerithroid для лечения гипотиреоза

Фармацевтическая компания Oliva Therapeutics представила Amerithroid — пероральный препарат на основе естественного экстракта щитовидной железы свиней, содержащий гормоны T4 и T3. Лекарство предназначено для замены или дополнения терапии у пациентов с гипотиреозом любой этиологии, а также для лечения зоба и профилактики рецидивов после операций по удалению щитовидной железы.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

Oliva Therapeutics has launched thyroid hormone replacement therapy Amerithroid™ (Thyroid Tablets, USP). Amerithroid is an oral, naturally prepared desiccated thyroid extract derived from porcine thyroid glands that contains both tetraiodothyronine (T4 levothyroxine) and triiodothyronine (T3 liothyronine). Specifically, it is indicated: - As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis; and - As pituitary thyroid stimulating hormone suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto), multinodular goiter, and in the management of thyroid cancer. Amerithroid tablets are supplied in the following dosage strengths: 15mg, 30mg, 60mg, 90mg, 120mg, 180mg, 240mg, and 300mg. The product provides approximately 38mcg levothyroxine and 9mcg liothyronine per grain of thyroid. The dosage is based on the indication and must be individualized according to patient response and laboratory findings. Caution should be exercised in high-risk cardiovascular patients, such as the elderly or those with angina pectoris. Patients receiving concomitant insulin or oral hypoglycemics should be closely monitored when initiating thyroid replacement therapy. Additionally, prothrombin time should be closely tracked in thyroid-treated patients on oral anticoagulants. References: - Oliva Therapeutics announces the launch of Amerithroid™ (thyroid tablets, USP), a naturally derived T3/T4 thyroid hormone replacement therapy. News release. Oliva Therapeutics. July 2, 2026. https://www.businesswire.com/news/home/20260702758888/en/Oliva-Therapeutics-Announces-the-Launch-of-Amerithroid-Thyroid-Tablets-USP-a-Naturally-Derived-T3T4-Thyroid-Hormone-Replacement-Therapy. - Amerithroid. Package insert. Oliva; 2026. Accessed on July 6, 2026. https://www.amerithroid.com/pi.